drugset
drugset / Trial / NCT03110484

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

NCT03110484 ↗

Phase 2 Unknown 44 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy

Timeline

Start
2021-07-09
Primary completion
2023-06-14
Completion
2024-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 100 mg —
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

biliary tract cancer